Author(s)

Kainan Wang

Corresponding Author

Kainan Wang

ABSTRACT

Non-small cell lung cancer (NSCLC) is a group of diseases that account for most lung cancer cases. Studies have shown that the cause of its mutation is the overexpression of epidermal growth factor receptor (EGFR) in human body. In this paper, the background, including the family of ErbB, of EGFR is given to show its importance in cancer therapy. The recent studies had developed inhibitors of EGFR that can slow or even prevent the reproduction of EGFR in human body. Some of the inhibitors are listed out in the paper, the brief summaries of their effect and usage have also been provided. Results for their trials on stage II and stage III patients are given to show their efficiency and safety.

KEYWORDS

Epidermal Growth Factor Receptor, Erlotinib, Afatinib, Gefitinib, Osimertinib, Trials